FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to new compounds of formula (I) 
, where Z means 
where R means hydrogen, C4-C6cycloalkyl group attached either through one of ring carbon atoms, or through a lower alkylene group attached to the ring, or a linearly chained or branched lower alkyl group or a lower hydroxyalkyl group, or a lower aminoalkyl group, or a phenyl(lower alkyl) group optionally substituted with 1-2 substitutes chosen from lower alkyl, lower alkoxy, halogen and hydroxy, or heteroaryl(lower alkyl)group where heteroaryl is chosen from the group consisting from thienyl, substituted with lower alkyl group, imidazolyl, and thiazolyl substituted with the lower alkyl group; n means 0 or 1; or Z means a group 
where R means the lower alkyl group; X1 means methylene or NH group; and X2 means methylene; or X1 means methylene and X2 means methylene or a bond; or X1 means methylene, and X2 means O, S or a bond; Y1 means methylene, and Y2 means methylene, vinylene, ethylene, or a bond; Ar1 means unsubstituted or substituted phenyl; Ar2 means unsubstituted or substituted phenyl, unsubstituted or substituted thienyl, unsubstituted or substituted furyl, unsubstituted or substituted pyridyl; and when Ar1 and Ar2 are substituted, each Ar1 and Ar2 are independently substituted with one or more substituted chosen from lower alkyl, lower alkoxy, hydroxy, lower hydroxyalkyl, halogen, di- and trihaloalkyl, di- and trihaloalkoxy, mono- and dialkylamino, alkilthio, alkyl ester and nitro; provided that Ar1 and Ar2 do not simultaneously mean unsubstituted phenyl; W means oxygen or sulphur; or to their pharmaceutically acceptable salts; provided those specified in cl. 1 of the patent claim. Besides the invention concerns the compounds chosen from the group, to compounds of formula (I), to pharmaceutical compositions, to a method of inhibition of monoamine receptor activity, to a method of inhibition of monoamine receptor activation, to a method of treating a diseased state associated with serotonin receptor, to a method of treating schizophrenia, to a method of treating migraine, and also to a method of treating psychosis.
EFFECT: preparation of the new biologically active compounds capable to inhibit monoamine receptor activity.
65 cl, 140 ex, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| N-SUBSTITUTED DERIVATIVES OF PIPERIDINE AS SEROTONIN RECEPTOR AGENTS | 2003 |
|
RU2320646C2 |
| DERIVATIVES OF PIPERIDINE, METHODS FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2001 |
|
RU2298550C2 |
| MUSCARINIC AGONISTS | 2001 |
|
RU2269523C2 |
| NOVEL COMPOUNDS | 2001 |
|
RU2419608C2 |
| BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | 2017 |
|
RU2769827C2 |
| NOVEL INDOLE AND PYRROLE COMPOUNDS, A METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2014 |
|
RU2693404C2 |
| METHOD FOR PRODUCTION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ON CARBONITRYLES | 2003 |
|
RU2309149C2 |
| 8-METHYL-1-PHENYLIMIDAZO[1,5-a]PYRAZINE COMPOUNDS | 2011 |
|
RU2560162C2 |
| DERIVATIVES OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES AND RESPIRATORY WAYS DISEASES | 2001 |
|
RU2265011C2 |
| OXYINDOLE DERIVATIVES POSSESSING AGONIST ACTIVITY ON MOTILIN RECEPTOR | 2010 |
|
RU2533116C2 |
